Measles can lead to otitis media, tracheitis, encephalitis and other complications.Mumps can cause hearing loss and inflammation of the ovaries or testes.German measles can lead to arthritis, encephalitis, conjunctivitis, miscarriage or birth defects.
Due to the COVID-19 pandemic, the global Measles, Mumps and Rubella (MMR) Vaccines market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Measles, Mumps and Rubella (MMR) Vaccines market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Measles, Mumps and Rubella (MMR) Vaccines landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Monovalent Vaccine accounting for % of the Measles, Mumps and Rubella (MMR) Vaccines global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Immune Center segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Measles, Mumps and Rubella (MMR) Vaccines include Medlmmune, Johnson & Johnson, Merck, Sanofi, Serum, Bavarian Nordic, Astellas Pharma, Emergent BioSolutions and GlaxoSmithKline, etc. In terms of revenue, the global 3 largest players have a % market share of Measles, Mumps and Rubella (MMR) Vaccines in 2021.
This report focuses on Measles, Mumps and Rubella (MMR) Vaccines volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Measles, Mumps and Rubella (MMR) Vaccines market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Measles, Mumps and Rubella (MMR) Vaccines Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Monovalent Vaccine
Polyvalent Vaccine
Segment by Application
Immune Center
Vaccine Development Agencies and Organizations
Hospital
Laboratory
Biotechnology and Biopharmaceutical Companies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Medlmmune
Johnson & Johnson
Merck
Sanofi
Serum
Bavarian Nordic
Astellas Pharma
Emergent BioSolutions
GlaxoSmithKline
Pfizer
CSL